Key facts
- It has raised $50K; the latest was Seed Round ($50K) in May 2025.
- Mind Pharmaceuticals has filed 1 Form D with the SEC, most recently May 2025 ($50K sold to 1 investors).
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Mind Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Mind Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mind Pharmaceuticals
Developer of sustained efficacy drugs designed to treat depression and headache disorders. The company develops antidepressant drugs for headache disorders like migraines and cluster headaches and provides treatment for resistant depression, enabling patients to democratize mental health and well-being.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2024
- Website
- mind-pharma.com/
- Ownership
- Privately Held (backing)
Mind Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mind Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mind Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.